Main | Bayer Discloses Trasylol (aprotinin) Trials Not Disclose Facts »

FDA Meeting on Trasylol

On September 21, 2006, FDA held a public meeting of the Cardiovascular and Renal Drugs Advisory Committee to discuss the safety and overall risk-benefit profile for Trasylol.

Posted by Michael Monheit on September 21, 2006 06:05 AM |

TrackBack

TrackBack URL for this entry:
http://blogs.legalview.com/mt-admin/mt-tb.cgi/393

Post a comment

(If you haven't left a comment here before, you may need to be approved by the site owner before your comment will appear. Until then, it won't appear on the entry. Thanks for waiting.)